Biopharma · FDA Approvals · Stock
LUCD Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophagea…
Assets on file: EsoGuard
Catalyst calendar
Dated catalysts for LUCD, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for LUCD, newest first.
LUCDLucid DiagnosticsLucid Diagnostics: Medicare Panel Recommends EsoGuard Gapfill Payment; New CPT Code Approved
A Medicare Advisory Panel recommended maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule. The AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck.
Peers by market cap
Companies in the same sector closest to LUCD in market value.
ONCYOncolytics BiotechMarket cap $65.6M · 1 tracked drug · 3 upcoming catalysts
VRCAVerrica PharmaceuticalsMarket cap $65.8M · 1 tracked drug · 3 upcoming catalysts
TENXTenax TherapeuticsMarket cap $65.9M · 1 tracked drug · 2 upcoming catalysts
FBIOFortress BiotechMarket cap $66.4M · 1 tracked drug
CGTXCognition TherapeuticsMarket cap $66.6M · 1 tracked drug · 1 upcoming catalyst
OSTXOS TherapiesMarket cap $58.5M · 1 tracked drug
LFSLeifrasMarket cap $58.3M · 1 tracked drug
GOSSGossamer BioMarket cap $57.9M · 1 tracked drug · 3 upcoming catalysts